Clinical Trials Logo

Lungcancer clinical trials

View clinical trials related to Lungcancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06036563 Recruiting - Breast Cancer Clinical Trials

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to screen and differentiate common cancers in participants with or without suspicious lesions. The main question the investigators aim to answer is: Can the developed model, using peripheral blood cell-free DNA sequencing, work well in screening and classifying common cancers especially in the early stages? Participants will undergo the collection of 15~20ml of blood and 1~2 telephone follow-up calls.

NCT ID: NCT03020251 Recruiting - Lungcancer Clinical Trials

Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer

Rexochir
Start date: May 12, 2017
Phase: N/A
Study type: Interventional

This randomized controlled trial will evaluate the effect of a preoperative rehabilitation program at home in patients resected for lung cancer, comparing a control group (C group) receiving only chest physiotherapy and a rehabilitation group (R group) receiving both a training program at home and chest physiotherapy

NCT ID: NCT02977663 Recruiting - Lungcancer Clinical Trials

Imaging Multiparametric/Multimodality for Lungcancer

IRMomics
Start date: August 28, 2017
Phase: N/A
Study type: Interventional

1. To build an imaging biobank of 200 patients with lungcancer, including pathologic and molecular characteristics of the tumor (mutational status, circulating DeoxyriboNucleic Acid (DNA) from serum biobankā€¦), staging of the cancer (according to the new 2016 Tumor Node Metastasis (TNM) status, the table that classify non-small cell lungcancer) and follow-up informations (Response to first-line treatment (Response Evaluation Criteria in Solid Tumors (RECIST)), disease-free survival, 1-3 years survival). 2. To propose a simple severity scoring system based on tumor features such as size, doubling time (if available), location, amount of enhancement and necrosis. Such approach has been proposed for glioma evaluation (Visually Accessible Rembrandt Images (VASARI)) but is not available for the lung. The objective is to do better than the Tumor Node Metastasis (TNM) staging. 3. To develop and evaluate an IntraVoxel Incoherent Motion (IVIM) protocol for lungcancer evaluation.